Clinical, biologic, and molecular features of CLL patients included in the study
| Parameter . | No. (%) of patients . |
|---|---|
| Total patients | 449 |
| Age, y | 449 (100) |
| Median | 65 |
| Range | 33-89 |
| Sex | 449 (100) |
| Female | 167 (37.2) |
| Male | 282 (62.8) |
| Binet stage | 449 (100) |
| A | 331 (73.7) |
| B | 67 (14.9) |
| C | 51 (11.4) |
| ZAP-70 expression | 401 (89.3) |
| Negative | 261 (65.1) |
| Positive | 140 (34.9) |
| CD38 expression | 410 (91.3) |
| Negative | 330 (80.5) |
| Positive | 80 (19.5) |
| IGHV mutational status | 379 (84.4) |
| Mutated | 249 (65.7) |
| Unmutated | 130 (34.3) |
| FISH analysis | 303 (67.5) |
| Normal | 135 (44.6) |
| 13q14.3 | 83 (27.4) |
| Trisomy 12 | 32 (10.6) |
| 11q22.3 | 29 (9.6) |
| 17p13.1 | 24 (7.9) |
| Parameter . | No. (%) of patients . |
|---|---|
| Total patients | 449 |
| Age, y | 449 (100) |
| Median | 65 |
| Range | 33-89 |
| Sex | 449 (100) |
| Female | 167 (37.2) |
| Male | 282 (62.8) |
| Binet stage | 449 (100) |
| A | 331 (73.7) |
| B | 67 (14.9) |
| C | 51 (11.4) |
| ZAP-70 expression | 401 (89.3) |
| Negative | 261 (65.1) |
| Positive | 140 (34.9) |
| CD38 expression | 410 (91.3) |
| Negative | 330 (80.5) |
| Positive | 80 (19.5) |
| IGHV mutational status | 379 (84.4) |
| Mutated | 249 (65.7) |
| Unmutated | 130 (34.3) |
| FISH analysis | 303 (67.5) |
| Normal | 135 (44.6) |
| 13q14.3 | 83 (27.4) |
| Trisomy 12 | 32 (10.6) |
| 11q22.3 | 29 (9.6) |
| 17p13.1 | 24 (7.9) |